ofDiabetes,2020,11(1):1-124莫帅帅,孙立娟.超重/肥胖2型糖尿病患者腹部脂肪分布与胰岛素抵抗的相关性[J].中国实验诊断学,2020,24(1):57-595FadiniGP,ZattiG,BaldiI,etal.Useandeffectivenessofdapagli-flozininroutineclinicalpractice.AnItalianmulticenterretrospectivestudy[J].DiabetesObesity&Metabolism,2018,20(7):1781-17866梁斌,李兰,魏东.聚乙二醇洛塞那肽联合二甲双胍对2型糖尿病患者的临床疗效[J].川北医学院学报,2021,36(2):246-2497JourdanT,GodlewskiG,KunosG.Endocannabinoidregulationofβ-cellfunctions:implicationsforglycemiccontrolanddiabetes[J].Diabetes,ObesityandMetabolism,2016,18(6):549-5578陈颖,夏明锋,李小英.体脂分布与糖尿病风险[J].中国糖尿病杂志,2017,9(4):218-2209DaviesMJ,DaD′Alessio,FradkinJ,etal.Managementofhypergly-cemiaintype2diabetes,2018.AconsensusreportbytheAmericanDiabetesAssociation(ADA)andtheEuropeanAssociationfortheStudyofDiabetes(EASD)[J].DiabetesCare,2018,41(12):2669-270110朱延华,翁建平.胰高血糖素样肽-1受体激动剂类药物的临床应用[J].中国实用内科杂志,2014,10:942-94611AndersonJE.Combiningglucagon-likepeptide1receptoragonistsandsodium-glucosecotransporter2inhibitorstotargetmultipleorgandefectsintype2diabetes[J].DiabetesSpectrum,2020,33(2):165-17412温彩霞,杨晓燕,徐卫娟,等.利拉鲁肽联合达格列净对超重或肥胖2型糖尿病患者肾功能、氧化应激以及内脏脂肪含量的影响[J].现代生物医学进展,2021,21(12):2271-2274,229713菅小红,徐建宾,申晶.达格列净对中心肥胖型新诊断T2MD患者β胰岛细胞功能和脂代谢紊乱的影响[J].国际检验医学杂志,2019,40(10):63-6614ChenX,LüX,YangG,etal.Polyethyleneglycolloxenatideinjec-tionsaddedtometformineffectivelyimproveglycemiccontrolandex-hibitfavorablesafetyintype2diabeticpatients[J].JDiabetes,2017,9(2):158-16715姚璐,武云涛,田国祥,等.聚乙二醇洛塞那肽注射液联合二甲双胍对2型糖尿病患者的疗效[J].中国循证心血管医学杂志,2017,9(5):577-57916MillarP,PathakN,ParthsarathyV,etal.Metabolicandneuropro-tectiveeffectsofdapagliflozinandliraglutideindiabeticmice[J].JEndocrinol,2017,234(3):255-26717李芝,李堃宜,钟志鹏,等.聚乙二醇洛塞那肽联合达格列净治疗肥胖2型糖尿病患者的疗效及安全性研究[...
